{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:18:04Z","timestamp":1783113484768,"version":"3.54.6"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: The objective of this study was to describe the rates of adverse clinical outcomes, including all-cause mortality, heart failure (HF) hospitalization, myocardial infarction, and stroke, in patients newly diagnosed with HF to provide a comprehensive picture of HF burden. Methods: This was a retrospective and observational study, using the BIG-PAC database in Spain. Adults, newly diagnosed with HF between January 2013 and September 2019 with \u22651 HF-free year of enrolment prior to HF diagnosis, were included. Results: A total of 19,961 patients were newly diagnosed with HF (43.5% with reduced ejection fraction (EF), 26.3% with preserved EF, 5.1% with mildly reduced EF, and 25.1% with unknown EF). The mean age was 69.7 \u00b1 19.0 years; 53.8% were men; and 41.0% and 41.5% of patients were in the New York Heart Association functional classes II and III, respectively. The baseline HF treatments included beta-blockers (70.1%), renin\u2013angiotensin system inhibitors (56.3%), mineralocorticoid receptor antagonists (11.8%), and SGLT2 inhibitors (8.9%). The post-index incidence rates of all-cause mortality, HF hospitalization, and both combined were 102.2 (95% CI 99.9\u2013104.5), 123.1 (95% CI 120.5\u2013125.7), and 182 (95% CI 178.9\u2013185.1) per 1000 person-years, respectively. The rates of myocardial infarction and stroke were lower (26.2 [95% CI 25.1\u201327.4] and 19.8 [95% CI 18.8\u201320.8] per 1000 person-years, respectively). Conclusions: In Spain, patients newly diagnosed with HF have a high risk of clinical outcomes. Specifically, the rates of all-cause mortality and HF hospitalization are high and substantially greater than the rates of myocardial infarction and stroke. Given the burden of adverse outcomes, these should be considered targets in the comprehensive management of HF. There is much room for improving the proportion of patients receiving disease-modifying therapies.<\/jats:p>","DOI":"10.3390\/jcm12062410","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:48:01Z","timestamp":1679374081000},"page":"2410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-4735","authenticated-orcid":false,"given":"Carlos","family":"Escobar","sequence":"first","affiliation":[{"name":"Cardiology Department, University Hospital La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0089-2291","authenticated-orcid":false,"given":"Beatriz","family":"Palacios","sequence":"additional","affiliation":[{"name":"AstraZeneca Farmaceutica, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"AstraZeneca Farmaceutica, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1882-5433","authenticated-orcid":false,"given":"Mart\u00edn","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"AstraZeneca Farmaceutica, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Duong","sequence":"additional","affiliation":[{"name":"Evidera, London W6 8BJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-7299","authenticated-orcid":false,"given":"Nahila","family":"Justo","sequence":"additional","affiliation":[{"name":"Evidera, 113 21 Stockholm, Sweden"},{"name":"Karolinska Institute, Department of Neurobiology, Care Sciences, and Society, 171 77 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cid-Ruzafa","sequence":"additional","affiliation":[{"name":"Evidera, 08005 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Atrys Health, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-175X","authenticated-orcid":false,"given":"Phillip R.","family":"Hunt","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-8324","authenticated-orcid":false,"given":"Juan F.","family":"Delgado","sequence":"additional","affiliation":[{"name":"Cardiology Department, University Hospital 12 de Octubre, CIBERCV, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of Heart Failure. A Contemporary Perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1097\/MJT.0000000000000794","article-title":"The Vulnerable Phase of Heart Failure","volume":"25","author":"Gracia","year":"2018","journal-title":"Am. J. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart failure after myocardial infarction: Incidence and predictors","volume":"8","author":"Stehlik","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/1755-5922.12180","article-title":"Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review","volume":"34","author":"Lavoie","year":"2016","journal-title":"Cardiovasc. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hfc.2013.10.002","article-title":"The role of coronary artery disease in heart failure","volume":"10","author":"Lala","year":"2014","journal-title":"Heart Fail. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1161\/STROKEAHA.111.628479","article-title":"Chronic heart failure and ischemic stroke","volume":"42","author":"Haeusler","year":"2011","journal-title":"Stroke"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"967197","DOI":"10.3389\/fcvm.2022.967197","article-title":"Prevalence and incidence of stroke, white matter hyperintensities, and silent brain infarcts in patients with chronic heart failure: A systematic review, meta-analysis, and meta-regression","volume":"9","author":"Tan","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/ehf2.13885","article-title":"Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction","volume":"9","author":"Hamada","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ehf2.13742","article-title":"Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: An observational study","volume":"9","author":"Vaartjes","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Escobar, C., Palacios, B., Varela, L., Guti\u00e9rrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hern\u00e1ndez, I., and Hunt, P.R. (2022). Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. J. Clin. Med., 11.","DOI":"10.21203\/rs.3.rs-1900010\/v1"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Escobar, C., Palacios, B., Varela, L., Guti\u00e9rrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hern\u00e1ndez, I., and Hunt, P.R. (2022). Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08614-x"},{"key":"ref_15","first-page":"31","article-title":"Epidemiology and treatment of heart failure in Spain: The HF-PATHWAYS study","volume":"75","author":"Palacios","year":"2022","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00392-014-0788-x","article-title":"Sex differences in new-onset heart failure","volume":"104","author":"Meyer","year":"2015","journal-title":"Clin. Res. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"Lippi","year":"2020","journal-title":"AME Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_19","first-page":"347","article-title":"Prognostic Impact of Physician Specialty on the Prognosis of Outpatients With Heart Failure: Propensity Matched Analysis of the REDINSCOR and RICA Registries","volume":"70","author":"Puig","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl. Ed)."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/CLEP.S341919","article-title":"Characterizing a Clinical Trial Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Wells","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply\u201d?","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Digitalis Investigation Group (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. N. Eng. J. Med., 336, 525\u2013533.","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":":e021660","DOI":"10.1161\/JAHA.121.021660","article-title":"Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study","volume":"11","author":"John","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cardfail.2018.09.013","article-title":"First Hospitalization for Heart Failure in Outpatients With Stable Coronary Artery Disease: Determinants, Role of Incident Myocardial Infarction, and Prognosis","volume":"24","author":"Lamblin","year":"2018","journal-title":"J. Card. Fail."},{"key":"ref_32","first-page":"1142","article-title":"Clinical features and prognosis of patients with different types of heart failure in relation to coronary artery disease","volume":"100","author":"Zhou","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11897-018-0405-9","article-title":"Heart Failure and Stroke","volume":"15","author":"Schumacher","year":"2018","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Barkhudaryan, A., Doehner, W., and Scherbakov, N. (2021). Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051146"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:59:31Z","timestamp":1760122771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12062410"],"URL":"https:\/\/doi.org\/10.3390\/jcm12062410","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}